Hubei Biocause Pharmaceutical Valuation

Is 000627 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000627 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 000627's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 000627's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000627?

Key metric: As 000627 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 000627. This is calculated by dividing 000627's market cap by their current revenue.
What is 000627's PS Ratio?
PS Ratio	0.5x
Sales	CN¥40.70b
Market Cap	CN¥19.81b

000627 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	-21.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 000627's PS Ratio compare to its peers?

The above table shows the PS ratio for 000627 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.2x
601336 New China Life Insurance	2.4x	-1.6%	CN¥120.1b
601318 Ping An Insurance (Group) Company of China	1x	-8.4%	CN¥875.1b
GNW Genworth Financial	0.4x	n/a	US$3.3b
TLI Thai Life Insurance	1.1x	4.5%	฿119.1b
000627 Hubei Biocause Pharmaceutical	0.5x	n/a	CN¥19.8b

Price-To-Sales vs Peers: 000627 is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does 000627's PS Ratio compare vs other companies in the Asian Insurance Industry?

20 Companies	Price / Sales	Estimated Growth	Market Cap

20 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 000627 is good value based on its Price-To-Sales Ratio (0.5x) compared to the Asian Insurance industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is 000627's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000627 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 000627's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Life Insurance

HK$1.0t

Operates as a life insurance company in the People’s Republic of China.

601628

HK$41.77

-6.5%

33.2%

New China Life Insurance

CN¥120.1b

Provides life insurance products and services to individuals and institutions in China.

601336

CN¥47.01

-6.7%

46.7%

China Pacific Insurance (Group)

CN¥294.9b

Provides insurance products to individual and institutional customers in the People’s Republic of China.

601601

CN¥33.85

-3.5%

37.4%